JP2000500479A5 - - Google Patents

Download PDF

Info

Publication number
JP2000500479A5
JP2000500479A5 JP1997519454A JP51945497A JP2000500479A5 JP 2000500479 A5 JP2000500479 A5 JP 2000500479A5 JP 1997519454 A JP1997519454 A JP 1997519454A JP 51945497 A JP51945497 A JP 51945497A JP 2000500479 A5 JP2000500479 A5 JP 2000500479A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1997519454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000500479A (ja
Filing date
Publication date
Priority claimed from FR9513956A external-priority patent/FR2741621B1/fr
Application filed filed Critical
Publication of JP2000500479A publication Critical patent/JP2000500479A/ja
Publication of JP2000500479A5 publication Critical patent/JP2000500479A5/ja
Pending legal-status Critical Current

Links

JP9519454A 1995-11-23 1996-11-21 ピラゾール誘導体、その製造方法、および該誘導体を含む医薬組成物 Pending JP2000500479A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9513956A FR2741621B1 (fr) 1995-11-23 1995-11-23 Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR95/13956 1995-11-23
PCT/FR1996/001847 WO1997019063A1 (fr) 1995-11-23 1996-11-21 Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
JP2000500479A JP2000500479A (ja) 2000-01-18
JP2000500479A5 true JP2000500479A5 (enExample) 2004-10-21

Family

ID=9484869

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9519454A Pending JP2000500479A (ja) 1995-11-23 1996-11-21 ピラゾール誘導体、その製造方法、および該誘導体を含む医薬組成物

Country Status (16)

Country Link
US (1) US6028084A (enExample)
EP (1) EP0876350B1 (enExample)
JP (1) JP2000500479A (enExample)
AT (1) ATE203015T1 (enExample)
AU (1) AU7698596A (enExample)
BR (1) BR9611618A (enExample)
CA (1) CA2238430C (enExample)
DE (1) DE69613860T2 (enExample)
DK (1) DK0876350T3 (enExample)
ES (1) ES2161382T3 (enExample)
FR (1) FR2741621B1 (enExample)
GR (1) GR3036830T3 (enExample)
MX (1) MX9803891A (enExample)
NO (1) NO310508B1 (enExample)
PT (1) PT876350E (enExample)
WO (1) WO1997019063A1 (enExample)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2283797A1 (en) * 1997-03-18 1998-09-24 Paul Elliot Bender Novel cannabinoid receptor agonists
EP1071419B1 (en) 1998-04-21 2007-07-25 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Cannabinoids as antioxidants and neuroprotectants
ATE247097T1 (de) * 1998-05-04 2003-08-15 Univ Connecticut Analgetische und immunomodulierende cannabinoiden
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
WO2001028329A1 (en) 1999-10-18 2001-04-26 University Of Connecticut Peripheral cannabinoid receptor (cb2) selective ligands
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
US6974568B2 (en) * 2000-05-23 2005-12-13 The Regents Of The University Of California Treatment for cough
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
CA2435409A1 (en) * 2001-01-26 2002-08-01 University Of Connecticut Novel cannabimimetic ligands
DE60237431D1 (de) 2001-01-29 2010-10-07 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
CA2452881C (en) * 2001-07-13 2012-03-06 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
AU2002319627A1 (en) * 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
EP1448557A4 (en) * 2001-10-26 2005-02-02 Univ Connecticut HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
WO2003077847A2 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
CA2479618A1 (en) * 2002-03-26 2003-10-09 William K. Hagmann Spirocyclic amides as cannabinoid receptor modulators
WO2003082191A2 (en) * 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
WO2003087037A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
WO2003086288A2 (en) * 2002-04-12 2003-10-23 Merck & Co., Inc. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
CN100486973C (zh) 2002-07-29 2009-05-13 霍夫曼-拉罗奇有限公司 新苯并间二氧杂环戊烯类
CA2494091C (en) * 2002-08-02 2011-02-01 Richard B. Toupence Substituted furo [2,3-b| pyridine derivatives
AU2003265663A1 (en) 2002-08-23 2004-03-11 University Of Connecticut Keto cannabinoids with therapeutic indications
HRP20050053A2 (en) * 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
US7765162B2 (en) * 2002-10-07 2010-07-27 Mastercard International Incorporated Method and system for conducting off-line and on-line pre-authorized payment transactions
SE0203070D0 (en) 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
ITMI20022228A1 (it) * 2002-10-21 2004-04-22 Dinamite Dipharma S P A Sali di clopidogrel con acidi alchil-solforici.
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CA2511859A1 (en) 2003-01-02 2004-07-22 Alexander Mayweg Novel cb 1 receptor inverse agonists
ATE400571T1 (de) 2003-01-02 2008-07-15 Hoffmann La Roche Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
DE602004012858T2 (de) 2003-06-20 2009-05-14 F. Hoffmann-La Roche Ag 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
FR2856684B1 (fr) * 2003-06-26 2008-04-11 Sanofi Synthelabo Derives de diphenylpyridine, leur preparation et leur application en therapeutique
US7754188B2 (en) * 2003-06-30 2010-07-13 Merck Sharp & Dohme Corp. Radiolabeled cannabinoid-1 receptor modulators
US20050026983A1 (en) * 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
RU2361868C2 (ru) 2003-12-08 2009-07-20 Ф.Хоффманн-Ля Рош Аг Новые производные тиазола
TW200522944A (en) * 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
CN100572375C (zh) 2004-01-28 2009-12-23 霍夫曼-拉罗奇有限公司 螺-苯并间二氧杂环戊烯及其作为cb1拮抗剂的应用
AU2005230864A1 (en) 2004-03-29 2005-10-20 Merck Sharp & Dohme Corp. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
MXPA06012813A (es) 2004-05-10 2007-01-26 Hoffmann La Roche Pirrol o imidazol amidas para tratar la obesidad.
ITMI20041033A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
ITMI20041032A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
BRPI0513104A (pt) 2004-07-12 2008-04-29 Cadila Healthcare Ltd composto, composição farmacêutica, método para o tratamento de doenças associadas com os receptores de canabinóide, medicamento para o tratamento/redução de doenças associadas com os receptores de canabinóides, uso do composto, processo para a preparação do composto e intermediário
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
ATE472531T1 (de) 2004-08-06 2010-07-15 Merck Sharp & Dohme Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
FR2874012B1 (fr) 2004-08-09 2008-08-22 Sanofi Synthelabo Derives de pyrrole, leur preparation et leur utlisation en therapeutique
EP1784390A2 (en) * 2004-08-13 2007-05-16 Amgen Inc. Substituted benzofused heterocycles
US20060069080A1 (en) * 2004-09-29 2006-03-30 Veltri Enrico P Combinations of substituted azetidinones and CB1 antagonists
JP2008517959A (ja) 2004-10-27 2008-05-29 エフ.ホフマン−ラ ロシュ アーゲー 新規なインドール又はベンゾイミダゾール誘導体
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CN101094689B (zh) 2004-11-01 2013-06-12 安米林药品有限责任公司 治疗肥胖以及肥胖相关疾病和病症的方法
CA2586068A1 (en) 2004-11-09 2006-05-18 F.Hoffmann-La Roche Ag Dibenzosuberone derivatives
EP1833802A2 (en) * 2004-12-23 2007-09-19 AstraZeneca AB 1,2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
US20080146614A1 (en) * 2004-12-23 2008-06-19 Leifeng Cheng Therapeutic Agents
US8853205B2 (en) 2005-01-10 2014-10-07 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
AU2006203845A1 (en) * 2005-01-10 2006-07-13 Alexandros Makriyannis Novel heteropyrrole analogs acting on cannabiniod receptors
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
DE602006007563D1 (de) * 2005-04-06 2009-08-13 Hoffmann La Roche Agonisten
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20060278280A1 (en) * 2005-05-23 2006-12-14 Tzai-Jen Yang Check valve
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
WO2006129826A1 (ja) 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
MX2007015779A (es) * 2005-06-22 2008-02-22 Hoffmann La Roche (6-fluoro-benzo[1,3]dioxolil)-morfolin-4-il-metanonas y su uso como ligandos cb1.
CA2518579A1 (en) * 2005-08-05 2007-02-05 University Technologies International Inc. Method for appetite suppression
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP1921065B1 (en) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
CA2629018C (en) 2005-11-10 2013-12-31 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
US7687481B2 (en) * 2006-03-10 2010-03-30 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
US7629346B2 (en) * 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) * 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
CA2664358A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diarylketimine derivative
US20080108643A1 (en) * 2006-11-03 2008-05-08 Forest Laboratories Holdings Limited Method for treating autism
JP5437812B2 (ja) 2006-12-18 2014-03-12 7ティーエム ファーマ エイ/エス Cb1受容体モジュレーター
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
PE20090142A1 (es) * 2007-04-11 2009-02-19 Merck & Co Inc Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2010001242A (es) * 2007-07-30 2010-07-02 Alltranz Inc Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos.
US8133904B2 (en) * 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
UA97707C2 (ru) * 2007-11-14 2012-03-12 Амилин Фармасьютикалз, Инк. Способы лечения ожирения и заболеваний, расстройств, связанных с ожирением
CN101896465A (zh) * 2007-12-10 2010-11-24 7Tm制药联合股份有限公司 大麻素受体调节剂
EP2254601B1 (en) * 2008-02-08 2019-05-29 Nektar Therapeutics Oligomer-cannabinoid conjugates
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Msd株式会社 アルキルアミノピリジン誘導体
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
EP2149370A1 (en) 2008-07-31 2010-02-03 Neuroscienze Pharmaness S.C. A R.L. Diazabicyclic compounds and microemulsions thereof
IT1390848B1 (it) 2008-07-31 2011-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
CN102264228A (zh) 2008-10-22 2011-11-30 默沙东公司 用于抗糖尿病药的新的环状苯并咪唑衍生物
NZ592544A (en) 2008-10-30 2013-01-25 Merck Sharp & Dohme Isonicotinamide orexin receptor antagonists
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8759539B2 (en) 2008-11-17 2014-06-24 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US10053444B2 (en) 2009-02-19 2018-08-21 University Of Connecticut Cannabinergic nitrate esters and related analogs
IT1394400B1 (it) 2009-02-25 2012-06-15 Neuroscienze Pharmaness S C Ar L Composizioni farmaceutiche
IT1395724B1 (it) 2009-02-25 2012-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
DE102009035649A1 (de) * 2009-07-29 2011-02-03 Siemens Aktiengesellschaft Arzneistoff und Verfahren zur Erprobung eines Arzneistoffes
AU2010317842A1 (en) 2009-11-16 2012-07-12 Mellitech [1,5]-diazocin derivatives
IT1396951B1 (it) 2009-12-18 2012-12-20 Neuroscienze Pharmaness S C A R L Composti farmaceutici
CA2784799C (en) 2009-12-30 2014-06-10 Shanghai Fochon Pharmaceutical Co Ltd Certain dipeptidyl peptidase inhibtors
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
EP2563764B1 (en) 2010-04-26 2015-02-25 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2579873A4 (en) 2010-06-11 2013-11-27 Merck Sharp & Dohme NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
EA025380B1 (ru) 2011-02-25 2016-12-30 Мерк Шарп Энд Домэ Корп. Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
AU2012316331B2 (en) * 2011-09-30 2016-02-25 National Health Research Institutes Pyrazole compounds
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EP2789619A1 (en) 2013-04-12 2014-10-15 Kemotech S.r.l. Pharmaceutical compounds wiht angiogenesis inbhibitory activity
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP6767878B2 (ja) 2014-06-06 2020-10-14 リサーチ トライアングル インスティテュート アペリン受容体(apj)アゴニストおよびそれらの使用
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
RU2021133849A (ru) 2015-12-09 2022-03-21 Рисерч Трайэнгл Инститьют Улучшенные агонисты апелинового рецептора (apj) и их использование
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
AU2019385644B2 (en) 2018-11-20 2025-10-30 Tes Pharma S.R.L. Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase
EP3924058B1 (en) 2019-02-13 2026-01-07 Merck Sharp & Dohme LLC 5-alkyl pyrrolidine orexin receptor agonists
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CA3125847A1 (en) 2020-07-27 2022-01-27 Makscientific, Llc Process for making biologically active compounds and intermediates thereof
US12054480B2 (en) 2020-07-31 2024-08-06 Makscientific, Llc Compounds for treating cannabinoid toxicity and acute cannabinoid overdose
AU2021329805B2 (en) 2020-08-18 2024-02-29 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3449350A (en) * 1968-06-24 1969-06-10 Ciba Geigy Corp Certain pyrazole-3-carboxylic acid hydrazide derivatives
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Similar Documents

Publication Publication Date Title
JP2000500228A5 (enExample)
JP2000500445A5 (enExample)
JP2000500033A5 (enExample)
JP2000500440A5 (enExample)
JP2000500479A5 (enExample)
JP2000500327A5 (enExample)
JP2000500406A5 (enExample)
JPH11509228A5 (enExample)
JP2000500361A5 (enExample)
JP2000500322A5 (enExample)
JP2000500258A5 (enExample)
JP2000500342A5 (enExample)
JP2000500192A5 (enExample)
JPH11508653A5 (enExample)
JPH11510488A5 (enExample)
JPH11510172A5 (enExample)
JP2000500226A5 (enExample)
JP2000500051A5 (enExample)
JP2000500397A5 (enExample)
JP2000500407A5 (enExample)
JP2000500019A5 (enExample)
JPH10508974A5 (enExample)
JP2000500346A5 (enExample)
JP2000500044A5 (enExample)
JP2000500429A5 (enExample)